Geron Corporation (Nasdaq: GERN) — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Financial statements are unaudited. Geron is a late-stage biopharmaceutical company focused on imetelstat; it reported no product revenue and is dependent on imetelstat’s development and potential commercialization.
Key financial metrics
| Metric | Q2 2023 / June 30, 2023 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $29,000 royalties | $73,000 in Q2 2022 |
| Research and development expense | $35.5 million | $20.6 million in Q2 2022 |
| General and administrative expense | $16.5 million | $7.4 million in Q2 2022 |
| Net loss | $49.2 million; $0.09 per share | $28.1 million; $0.07 per share in Q2 2022 |
| Six-month net loss | $87.3 million | $58.2 million in first half 2022 |
| Cash, cash equivalents, restricted cash and marketable securities | $400.2 million | $173.1 million at December 31, 2022 |
| Operating cash used | $76.0 million in first half 2023 | $62.6 million in first half 2022 |
| Debt | $50.0 million principal; $51.6 million net carrying value | $50.0 million principal at December 31, 2022 |
At June 30, 2023, current assets were $377.3 million and current liabilities were $72.6 million. Stockholders’ equity was $298.4 million and accumulated deficit was $1.501 billion. No operating margin is meaningful given the company’s minimal royalty revenue and lack of product sales.
Changes versus the prior comparable period
- Q2 operating expenses rose to $52.0 million from $28.0 million, primarily reflecting higher clinical, manufacturing, personnel and commercialization-preparation costs.
- Q2 net loss widened to $49.2 million from $28.1 million. Higher interest income ($4.7 million versus $0.3 million) partly offset increased operating costs and interest expense.
- First-half operating cash use increased by $13.4 million year over year, to $76.0 million.
- Liquidity increased following the January 2023 public offering, which generated $213.3 million net, and $77.6 million of first-half warrant-exercise proceeds. The company invested much of its funds in marketable securities.
- Common shares outstanding increased substantially: 521.9 million at June 30, 2023, compared with 390.3 million at December 31, 2022. The company also had 51.4 million pre-funded warrants outstanding.
Outlook, management commentary and key risks
- Geron submitted an NDA to the FDA in June 2023 for imetelstat in transfusion-dependent anemia in adults with lower-risk MDS after ESA failure, loss of response or ineligibility. It planned to submit a European MAA in Q4 2023. A potential U.S. launch was anticipated in the first half of 2024, conditional on regulatory review and approval; a potential European launch was projected by year-end 2024 if approved.
- Management estimated existing cash, cash equivalents, restricted cash and marketable securities would fund projected operations through the end of Q3 2025, incorporating an assumed U.S. launch in the first half of 2024 and updated IMpactMF timing. This is a forecast, not a guarantee; further funding may be needed sooner.
- Geron expected R&D and G&A expenses to increase as it advances clinical trials and prepares for potential commercialization. It expected 2023 royalties to be lower than 2022.
- IMpactMF was enrolling; management estimated its overall-survival interim analysis could occur in the first half of 2025 and final analysis in the first half of 2026. These event-driven timelines depend on enrollment and event rates. IMproveMF was enrolling, with early data expected at year-end 2023; the first patient in investigator-led IMpress was dosed in June 2023.
- Management cited clinical and regulatory uncertainty, imetelstat safety risks (including cytopenias, bleeding and liver toxicity), patient recruitment and retention, third-party manufacturing and supply constraints, competition, and the need for additional capital as material risks. One IMpactMF patient death was reported by the investigator as related to imetelstat.
- Outstanding debt is secured by substantially all company assets other than intellectual property and carries cash-balance and other covenants; Geron reported compliance at June 30, 2023. Up to $55 million remained potentially drawable, subject to milestones, other conditions and, for the final $25 million tranche, lender investment committee approval.
Contingencies and unusual items
- A proposed $24 million securities class-action settlement remained subject to final court approval; $17 million had been paid into escrow under insurance coverage, and Geron’s $7 million portion was accrued and payable in cash and/or shares after final approval. A final approval hearing was scheduled for August 24, 2023.
- A separate $1.35 million derivative-action settlement was paid in Q2 2023: $825,000 by Geron and $525,000 by insurers. The derivative actions described as covered by that settlement had been dismissed.
- Interest income rose substantially as the investment portfolio grew and yields increased. Available-for-sale securities had $980,000 of unrealized losses at June 30, 2023, attributed by the company to interest-rate changes rather than credit factors; no credit-loss allowance was recorded.
Most important facts for investors to verify
- FDA acceptance and review milestones for the NDA, and whether approval and the projected U.S. launch timing remain achievable.
- IMerge Phase 3 complete and longer-term results, including durability and safety, and whether the FDA considers the evidence sufficient.
- IMpactMF enrollment, event accrual and analysis timing, alongside progress and data from IMproveMF and IMpress.
- Cash burn, updated runway assumptions, commercial-preparation spending, and the availability and terms of remaining warrant proceeds or debt tranches.
- Final court approval and funding form for the $24 million class-action settlement, plus any additional legal exposure.
- Potential manufacturing inspection remediation, clinical supply sufficiency, and the extent of dilution from equity issuance, warrant exercises and pre-funded warrants.